Journal ArticleDOI
Simultaneous Delivery of siRNA and Paclitaxel via a “Two-in-One” Micelleplex Promotes Synergistic Tumor Suppression
Tianmeng Sun,Jin-Zhi Du,Yandan Yao,Chengqiong Mao,Shuang Dou,Songyin Huang,Pei-Zhuo Zhang,Kam W. Leong,Erwei Song,Jun Wang +9 more
Reads0
Chats0
TLDR
Clear evidence is shown that the micelleplex is capable of delivering siRNA and paclitaxel simultaneously to the same tumoral cells both in vitro and in vivo and can induce a synergistic tumor suppression effect in the MDA-MB-435s xenograft murine model.Abstract:
Combination of two or more therapeutic strategies with different mechanisms can cooperatively prohibit cancer development. Combination of chemotherapy and small interfering RNA (siRNA)-based therapy represents an example of this approach. Hypothesizing that the chemotherapeutic drug and the siRNA should be simultaneously delivered to the same tumoral cell to exert their synergistic effect, the development of delivery systems that can efficiently encapsulate two drugs and successfully deliver payloads to targeted sites via systemic administration has proven to be challenging. Here, we demonstrate an innovative “two-in-one” micelleplex approach based on micellar nanoparticles of a biodegradable triblock copolymer poly(ethylene glycol)-b-poly(e-caprolactone)-b-poly(2-aminoethyl ethylene phosphate) to systemically deliver the siRNA and chemotherapeutic drug. We show clear evidence that the micelleplex is capable of delivering siRNA and paclitaxel simultaneously to the same tumoral cells both in vitro and in v...read more
Citations
More filters
Journal ArticleDOI
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
TL;DR: It is anticipated that precisely engineered nanoparticles will emerge as the next-generation platform for cancer therapy and many other biomedical applications.
Journal ArticleDOI
Nanotechnology for Multimodal Synergistic Cancer Therapy
TL;DR: In this review, state-of-the-art studies concerning recent advances in nanotechnology-mediated multimodal synergistic therapy will be systematically discussed, with an emphasis on the construction of multifunctional nanomaterials for realizing bimodal and trimodal synergy therapy.
Journal ArticleDOI
Advanced materials and processing for drug delivery: The past and the future
TL;DR: In this review, this review focuses on the materials innovation and processing of drug delivery systems and how these advances have shaped the past and may influence the future of drug Delivery.
Journal ArticleDOI
Single-Step Assembly of DOX/ICG Loaded Lipid–Polymer Nanoparticles for Highly Effective Chemo-photothermal Combination Therapy
Mingbin Zheng,Caixia Yue,Yifan Ma,Ping Gong,Pengfei Zhao,Cuifang Zheng,Zonghai Sheng,Pengfei Zhang,Zhaohui Wang,Lintao Cai +9 more
TL;DR: The well-defined DINPs exhibited great potential in targeting cancer imaging and chemo-photothermal therapy and no tumor recurrence was observed after only a single dose of DINP with laser irradiation.
Journal ArticleDOI
Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles To Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo
Huan Meng,Wilson X. Mai,Haiyuan Zhang,Min Xue,Tian Xia,Sijie Lin,Xiang Wang,Yang Zhao,Zhaoxia Ji,Jeffrey I. Zink,Andre E. Nel +10 more
TL;DR: Proof-of-principle testing of the use of a dual drug/siRNA nanocarrier to overcome Dox resistance in a xenograft is provided and the first detailed analysis of the impact of heterogeneity in the tumor microenvironment on the efficacy of siRNA delivery in vivo is provided.
References
More filters
Journal ArticleDOI
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Ting-Chao Chou,Paul Talalay +1 more
TL;DR: A generalized method for analyzing the effects of multiple drugs and for determining summation, synergism and antagonism has been proposed and has been used to analyze experimental data obtained from enzymatic, cellular and animal systems.
Journal Article
A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs
Yasuhiro Matsumura,Hiroshi Maeda +1 more
TL;DR: It is speculated that the tumoritropic accumulation of smancs and other proteins resulted because of the hypervasculature, an enhanced permeability to even macromolecules, and little recovery through either blood vessels or lymphatic vessels in tumors of tumor-bearing mice.
Journal ArticleDOI
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis,Jonathan E. Zuckerman,Chung Hang Jonathan Choi,David Seligson,Anthony W. Tolcher,Christopher A. Alabi,Christopher A. Alabi,Yun Yen,Jeremy D. Heidel,Antoni Ribas +9 more
TL;DR: Evidence is provided of inducing an RNAi mechanism of action in a human from the delivered siRNA and the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for anRNAi mechanism from a patient who received the highest dose of the nanoparticles.
Journal ArticleDOI
Rational design of cationic lipids for siRNA delivery
Sean C. Semple,Akin Akinc,Jianxin Chen,Ammen P. Sandhu,Barbara L. Mui,Connie K Cho,Dinah W.Y. Sah,Derrick Stebbing,Erin J Crosley,Ed Yaworski,Ismail M. Hafez,J. Robert Dorkin,June Qin,Kieu Lam,Kallanthottathil G. Rajeev,Kim F. Wong,Lloyd Jeffs,Lubomir Nechev,Merete L. Eisenhardt,Muthusamy Jayaraman,Mikameh Kazem,Martin Maier,Masuna Srinivasulu,Michael J Weinstein,Qingmin Chen,Rene Alvarez,Scott A Barros,Soma De,Sandra K. Klimuk,Todd Borland,Verbena Kosovrasti,William Cantley,Ying K. Tam,Muthiah Manoharan,Marco A. Ciufolini,Mark A Tracy,Antonin de Fougerolles,Ian MacLachlan,Pieter R. Cullis,Thomas D. Madden,Michael J. Hope +40 more
TL;DR: The best-performing lipid recovered after screening (DLin-KC2-DMA) was formulated and characterized in SNALP and demonstrated to have in vivo activity at siRNA doses as low as 0.01 mg/kg in rodents and 0.1 mg/ kg in nonhuman primates, a substantial improvement over previous reports of in vivo endogenous hepatic gene silencing.
Journal ArticleDOI
RNAi-mediated gene silencing in non-human primates
Tracy Zimmermann,Amy C.H. Lee,Akin Akinc,Birgit Bramlage,David Bumcrot,Matthew N. Fedoruk,Jens Harborth,James Heyes,Lloyd Jeffs,Matthias John,Adam Judge,Kieu Lam,Kevin McClintock,Lubomir Nechev,Lorne R. Palmer,Timothy Racie,Ingo Röhl,Stephan Seiffert,Sumi Shanmugam,Vandana Sood,Jürgen Soutschek,Ivanka Toudjarska,Amanda J. Wheat,Ed Yaworski,William Zedalis,Victor Koteliansky,Muthiah Manoharan,Hans-Peter Vornlocher,Ian MacLachlan +28 more
TL;DR: It is shown that siRNAs, when delivered systemically in a liposomal formulation, can silence the disease target apolipoprotein B in non-human primates, supporting RNAi therapeutics as a potential new class of drugs.